A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946 (NCT06616766)
A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate the Safety, Tolerability, PK and Anti-tumor Activity of YH42946 in Patients With Locally Advanced or Metastatic Solid Tumors With HER2 Aberration and EGFR Exon 20 Insertion
🩺 Plain-English Summary (8th-Grade Level)
The goal of this YH42946-101 is to evaluate the safety, Tolerability, Pharmacokinetics and anti-tumor activity of YH42946 in patients with locally advanced of metastatic solid tumors with HER2 aberration and EGFR exon 20 insertions.
Who can join: Review the eligibility criteria below.
Location: Next Oncology Virginia — Fairfax, Virginia
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (8 Sites)
- Next Oncology Virginia — Fairfax, Virginia
- Seoul National University Bundang Hospital — Seongnam-si, Gyeonggi-do
- The Catholic Univ. of Korea St. Vincent's Hospital — Suwon, Gyeonggi-do
- Chungbuk National University Hospital — Cheongju-si, North Chungcheong
- Seoul National University Hospital — Seoul,
- Severance Hospital, Yonsei University — Seoul,
- Samsung Medical Center — Seoul,
- Asan Medical Center, University of Ulsan — Seoul,
📞 Contact the Study Coordinator
Phone: (822) 828-0576
Email: clinicaltrials@yuhan.co.kr
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in NSCLC (Non-small Cell Lung Cancer)
- Observational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform (ELEPHAS-01) — Los Angeles, California
- Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) — Birmingham, Alabama
Explore by condition: All NSCLC (Non-small Cell Lung Cancer) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.